Share: Industry Experts Provide Added Depth to Board of Directors and Advisory Board TransCode Therapeutics today announced that it has recently elected a Chairman of its Board of Directors, appointed two new Independent Directors to the Board, and appointed a new member to its Advisory Board. Philippe Calais, Pharm D, Ph.D., President, Chief Executive Officer and a director of MatriSys Bioscience, Inc., has been elected Chairman of the Board of Directors of TransCode. Dr. Calais has served on TransCode's Board of Directors since October 2018. With an extensive background in drug development, Dr. Calais' experience has been instrumental in advancing TransCode's lead therapeutic candidate, TTX-MC138, focused on treating metastatic cancer.